Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 11/20 | 0.51 |
| ▸ | FFAR4 | Q5NUL3 | 10/20 | 0.51 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17028704 | 0.81 | FFAR4 (0.56) | FFAR1FFAR4KCNA5KCNH2 | |
| SCHEMBL15265915 | 0.79 | FFAR4 (0.80) | FFAR1FFAR4 | |
| SCHEMBL17028629 | 0.79 | FFAR1 (0.56) | FFAR1FFAR4 | |
| SCHEMBL15265056 | 0.76 | FFAR4 (0.61) | FFAR1FFAR4 | |
| SCHEMBL17028732 | 0.73 | FFAR4 (0.65) | FFAR1FFAR4 | |
| SCHEMBL5199654 | 0.72 | KCNA5 (0.51) | FFAR1FFAR4KCNA5KCNH2AKR1C3 | |
| SCHEMBL5378079 | 0.69 | FFAR1 (0.52) | FFAR1 | |
| SCHEMBL15266060 | 0.69 | FFAR4 (0.69) | FFAR1FFAR4 | |
| SCHEMBL15266453 | 0.68 | FFAR4 (0.80) | FFAR1FFAR4 | |
| SCHEMBL13140201 | 0.68 | FFAR1 (0.69) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3107901-B1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | PIRAMAL ENTPR LTD (IN) | 2020-04-01 | — | — | EP | disclosed |
| US-10227360-B2 | Compounds for use as GPR120 agonists | Piramal Enterprises Limited (IN) | 2019-03-12 | — | — | US | disclosed |
| EP-3107901-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-28 | — | — | EP | disclosed |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2016-12-01 | — | — | US | disclosed |
| WO-2015125085-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | Piramal Enterprises Limited (IN) | 2015-08-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227360-B2 | Compounds for use as GPR120 agonists | GPR119, GPR55, GPR180 | FFAR1 11/4885FFAR4 26/4885KCNA5 1372/4885 |
| US-20160347768-A1 | COMPOUNDS FOR USE AS GPR120 AGONISTS | GPR119, GPR55, GPR180 | FFAR1 11/4885FFAR4 26/4885KCNA5 1372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.